Printer Friendly

NEORX RECEIVES $9 MILLION FROM DAVID BLECH

 NEORX RECEIVES $9 MILLION FROM DAVID BLECH
 SEATTLE, Dec. 18 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX)


announced today that it has received the $9 million balance of a previously announced $10 million financing agreement with David Blech. The terms of the agreement provide that NeoRx issue 10 million shares of common stock, 5 million five-year warrants to purchase common stock at $1.75 per share, and 5 million five-year warrants to purchase common stock at $2.50 per share. If all the warrants are exercised, NeoRx would ultimately realize total proceeds of $31 million.
 At an initial closing on Sept. 26, 1991, the company received $1 million cash and issued one million shares of common stock and warrants to purchase one million additional shares of common stock on the terms described above.
 Robert M. Littauer, vice president, chief financial officer and treasurer of NeoRx, stated, "We are very pleased to have concluded this financing and to have available not only the financial resources of the Blech organization, but their expertise in the biotechnology business. At our present cash burn rate, these proceeds, combined with our present cash reserves, will see us through fiscal 1993."
 NeoRx Corporation, incorporated in May 1984, is developing monoclonal antibody-based pharmaceutical products for in vivo detection and treatment of certain types of cancer. The company has three cancer therapy trials in progress and has filed for marketing approval with the FDA for two OncoTrac(R) imaging products to detect metastatic melanoma and small cell lung cancer.
 -0- 12/18/91
 /CONTACT: Robert M. Littauer, vice president, chief financial officer and treasurer of NeoRx, 206-286-2519; or Anthony J. Russo or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX) CO: NeoRx Corporation ST: Washington IN: MTC SU: FNC GK -- NY005 -- 3259 12/18/91 08:52 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 18, 1991
Words:301
Previous Article:WCI STEEL REPORTS PROFITABLE 1991 FISCAL YEAR
Next Article:OFFICE DEPOT COMPLETES 2 MILLION SHARE PUBLIC OFFERING
Topics:


Related Articles
NEORX INCREASES SIZE OF ITS BOARD OF DIRECTORS
NEORX ANNOUNCES FIRST QUARTER RESULTS FOR FISCAL 1992
NEORX RECEIVES FAVORABLE FDA REVIEW LETTER
LAWRENCE A. LOEB JOINS NEORX SCIENTIFIC ADVISORY BOARD
NEORX COMPLETES $9 MILLION FINANCING
RIBI IMMUNOCHEM: WARRANT EXERCISE CONTRIBUTES $5.8 MILLION TO RIBI BALANCE SHEET
D. BLECH & COMPANY EXERCISES UNDERWRITERS OPTION TO PURCHASE 500,000 DNA PLANT TECHNOLOGY COMMON SHARES
SCHRODER VENTURE ADVISERS, INC. MANAGED BIOTECHNOLOGY INVESTMENT GROUP L.L.C. (BIO) ACQUIRES 1.8 MILLION SHARES OF LXR BIOTECHNOLOGY, INC. FROM BLECH...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters